LBAL + Humira®
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Arthritis, Rheumatoid
Conditions
Arthritis, Rheumatoid
Trial Timeline
Apr 13, 2016 → Feb 23, 2018
NCT ID
NCT02746380About LBAL + Humira®
LBAL + Humira® is a phase 3 stage product being developed by Mochida Pharmaceutical for Arthritis, Rheumatoid. The current trial status is completed. This product is registered under clinical trial identifier NCT02746380. Target conditions include Arthritis, Rheumatoid.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02746380 | Phase 3 | Completed |
Competing Products
20 competing products in Arthritis, Rheumatoid
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tilmanocept | Navidea Biopharmaceuticals | Phase 1 | 25 |
| Tc99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |
| KPL-404 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2828360 + Placebo | Eli Lilly | Phase 2 | 52 |
| Investigational Medical Product (IMP) administered in parent study | Eli Lilly | Phase 3 | 77 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 47 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo + Risankizumab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Dose A VTX958 + Dose B VTX958 + Placebo | Ventyx Biosciences | Phase 2 | 47 |
| LY2127399 | Eli Lilly | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Sugar pill | Eli Lilly | Approved | 85 |
| Ixekizumab + Tirzepatide | Eli Lilly | Pre-clinical | 23 |
| Ixekizumab + Tirzepatide | Eli Lilly | Phase 3 | 77 |
| Baricitinib + TNF Inhibitor | Eli Lilly | Approved | 85 |
| Ixekizumab + Adalimumab | Eli Lilly | Approved | 85 |
| UBX0101 or placebo | Unity Biotechnology | Pre-clinical | 15 |